Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield-NE Hematologic Molecular Co…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - NebraskaPolicy M.77

    MA Oncology Testing: Hematologic Malignancy Molecular Diagnostics (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.77 alerts

    Get alerted when Policy M.77 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs coverage and medical necessity criteria for molecular diagnostic tests and panels used in evaluation, prognosis, and treatment selection for hematologic malignancies for Blue Cross Blue Shield - Nebraska members; applies to providers requesting preauthorization for these tests.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Oncology Testing: Hematologic Malignancy Molecular Diagnostics (Preauthorization Required)
    Policy CodePolicy M.77
    Change TypeAdministrative (no material clinical changes)
    Effective DateMay 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionSubmit prior authorization for listed molecular pathology/genomic procedure codes before performing testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    51+ genesBroad RNA fusion threshold
    Bone marrow or bloodSpecimen sources
    Allowed in specified relapse casesRepeat profiling
    JAK2/CALR/MPLMPN minimum genes
    Guideline-citedNCCN support
    M.77Policy ID

    Coverage and Medical Necessity Criteria

    Broad RNA Fusion Panels for Hematologic Malignancy

    Covered when ALL of the following are met

    Broad RNA fusion panel coverage for ALL: RNA fusion panel tests with 51 or more genes utilizing RNA analysis alone that are performed on hematologic malignancies.>=51 genes

    May be considered reasonable and necessary when the member is undergoing diagnostic workup for adult or pediatric acute lymphoblastic leukemia (ALL).

    Broad Molecular Profiling Panels For Hematologic Malignancies and Myeloid Malignancy Panels - Initial testing

    Covered when ANY of the following indications applies

    Indications for broad molecular profiling panels: Member is undergoing evaluation for acute myeloid leukemia (AML); OR member has newly diagnosed acute lymphoblastic leukemia (ALL); OR member has newly diagnosed myelodysplastic syndrome (MDS); OR member has suspected MDS AND other causes of cytopenia(s) have been ruled out; OR member is suspected to have a myeloproliferative neoplasm (MPN) AND (this is the member’s initial genetic evaluation OR previous results of JAK2, CALR, and MPL analysis were negative); OR member has a diagnosis of chronic myelogenous leukemia (CML) AND (progression to accelerated or blast phase OR BCR-ABL1 kinase domain mutation analysis negative); OR member has a diagnosis of diffuse large B-cell lymphoma.
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Oncology Testing: Hematologic Malignancy Molecular Diagnostics (Preauthorization Required)
    Policy CodePolicy M.77
    Change TypeAdministrative (no material clinical changes)
    Effective DateMay 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionSubmit prior authorization for listed molecular pathology/genomic procedure codes before performing testing.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProcedure and Billing CodesPrior Authorization, Documentation, and Operational NotesKey Terms and DefinitionsLine of Therapy ContextRequired and Recommended BiomarkersClinical Context and RationalePolicy Revision Timeline

    Panels performed on bone marrow or peripheral blood.

    Repeat Broad Molecular Profiling Panels

    Repeat panels may be considered reasonable and necessary when ANY of the following are met

    Repeat broad molecular profiling panels: Member with myelodysplastic syndrome (MDS) who has relapsed after allo-HCT; OR member with acute lymphoblastic leukemia (ALL) showing evidence of symptomatic relapse after maintenance therapy; OR member with acute myeloid leukemia (AML) who has relapsed or refractory disease after consolidation or progression on treatment.

    Repeat testing applies to panels performed on bone marrow or peripheral blood.

    Broad molecular profiling panels — initial indications

    Broad molecular profiling panels and myeloid malignancy panels in bone marrow or peripheral blood may be considered reasonable and necessary when ANY of the following are met:

    Broad panel indications: A. Evaluation for AML; OR B. Newly diagnosed ALL; OR C. Newly diagnosed MDS; OR D. Suspected MDS AND other causes of cytopenia(s) have been ruled out; OR E. Suspected MPN AND (initial genetic evaluation OR prior JAK2/CALR/MPL analysis negative); OR F. Diagnosis of CML AND (progression to accelerated or blast phase OR BCR-ABL1 kinase domain mutation analysis negative); OR G. Diagnosis of diffuse large B-cell lymphoma.

    Supported by policy text.

    Broad molecular profiling panels — not reasonable and necessary

    Broad molecular profiling panels and myeloid malignancy panels are considered not reasonable and necessary for all other indications.

    Not covered other indications: Any indication not explicitly listed in the covered criteria for broad molecular profiling or myeloid malignancy panels.

    If a multigene panel is performed, appropriate panel codes should be used; clinical criteria do not address liquid biopsies.

    AML focused molecular profiling panels

    Acute myeloid leukemia (AML) focused molecular profiling panels may be considered reasonable and necessary when ANY of the following are met:

    AML focused panels: Member has a suspected or confirmed diagnosis of acute myeloid leukemia (AML).

    AML-focused panels are not reasonable and necessary for indications other than AML.

    MPN molecular profiling panels

    Myeloproliferative neoplasm (MPN) molecular profiling panels may be considered reasonable and necessary when ALL of the following are met:

    MPN panel required genes: A. Member is suspected to have a myeloproliferative neoplasm (MPN); AND B. The panel includes at minimum testing of JAK2, CALR, and MPL.

    MPN panels are not reasonable and necessary for other indications.

    MRD testing

    Measurable (minimal) residual disease (MRD) analysis in bone marrow or peripheral blood may be considered reasonable and necessary when the member has ONE of the following diagnoses and has completed treatment (or a treatment cycle where specified):

    MRD covered diagnoses: 1) Acute lymphoblastic leukemia (ALL) after completion of a treatment cycle; OR 2) Multiple myeloma after completion of a treatment cycle; OR 3) Diffuse large B-cell lymphoma after completion of a treatment cycle; OR 4) Chronic lymphocytic leukemia (CLL) after the member has completed treatment.

    MRD methods may include NGS, PCR, or flow cytometry as appropriate per guidelines.

    Tumor-specific single-gene and targeted analyses

    Tumor-specific single-gene or targeted analyses may be considered reasonable and necessary for the listed indications:

    BCR-ABL1 kinase domain analysis: CML or Philadelphia-positive ALL AND inadequate initial response to TKI therapy OR loss of response OR progression to accelerated/blast phase OR relapsed/refractory disease.

    Tumor-specific BCR-ABL1 testing includes kinase domain analysis and qualitative/quantitative assays as clinically indicated.

    BCR-ABL1 FISH/qual/quant: Suspected MPN OR diagnostic workup for ALL, AML, CML, or lymphoblastic leukemia OR MRD/monitoring for ALL, AML, CML when a quantitative test is used and the provider is considering discontinuation of or has discontinued TKI therapy.

    Includes FISH, qualitative, and quantitative testing as appropriate.

    CALR variant analysis: Suspected MPN OR suspected MDS.

    Per NCCN recommendations for initial MPN/MDS workup.

    CEBPA variant analysis: Evaluation for AML.

    Used for prognostication and treatment planning in AML.

    FLT3 variant analysis: Suspected or confirmed AML OR diagnosis of ALL, MDS, or MPN.

    FLT3 testing recommended for prognostic stratification in AML and ALL.

    IDH1/IDH2 variant analysis: Diagnosis of AML.

    IDH1/2 testing indicated in AML evaluation.

    IGHV somatic hypermutation analysis: Workup for or diagnosis of CLL, SLL, primary cutaneous B-cell lymphoma, or other B-cell lymphomas.

    IGHV mutation status informs prognosis and therapy selection in CLL/SLL.

    JAK2 variant analysis: Suspected MPN OR ALL OR suspected MDS.

    JAK2 testing is part of MPN/MDS evaluation and may be included in panels.

    KIT variant analysis: Evaluation for systemic mastocytosis OR diagnosis of AML.

    KIT testing indicated for mastocytosis and some AML cases.

    MPL variant analysis: Suspected MPN OR suspected MDS.

    MPL testing included in MPN-directed panels.

    NPM1 variant analysis: Evaluation for AML.

    NPM1 testing recommended in AML workup.

    NTRK fusion analysis (FISH/IHC): Diagnosis of acute lymphoblastic leukemia (ALL) at any stage for risk stratification.

    NTRK fusion analysis may be performed by FISH or IHC per guideline guidance.

    TP53 variant analysis: Diagnosis of AML, CLL, or SLL OR diagnostic workup for mantle cell lymphoma or multiple myeloma.

    TP53 sequencing is recommended for prognostic and therapeutic decision-making.

    Cytogenetic testing

    Cytogenetic testing:

    PML/RARA rearrangement testing: PML/RARA rearrangement analysis via FISH in peripheral blood or bone marrow for initial diagnostic workup for acute myeloid leukemia (AML).

    Qualitative FISH and PCR are acceptable methods for PML-RARA detection.

    Red blood cell genotyping

    Transfusion/genotyping:

    RBC genotyping for multiple myeloma: Member has multiple myeloma AND is currently being treated or will be treated with an anti-CD38 monoclonal antibody.

    Consider baseline RBC phenotype and genotype prior to anti-CD38 therapy to mitigate serologic interference (AABB bulletin updated April 2024).

    Covered when consistent with NCCN guidance

    Coverage aligned with NCCN guideline–recommended testing for specific hematologic malignancies and indications

    General: Coverage follows NCCN recommendations: molecular testing (NGS panels or targeted analyses) for diagnosis, prognostication, therapy selection, monitoring, and MRD assessment as cited in the referenced NCCN guidelines.

    See tumor-specific nodes below.

    MPN/MPD: Molecular testing on blood or bone marrow for suspected myeloproliferative neoplasm; multigene NGS panel that includes JAK2, CALR, and MPL can be used instead of stepwise testing; post-diagnosis somatic mutation testing is recommended for prognostication.

    NCCN Myeloproliferative Neoplasms guidance.

    CML: Consider myeloid mutation panel testing for advanced-phase CML (accelerated/blast phase) and BCR-ABL1 kinase domain testing for inadequate response, loss of response, 1-log increase in transcript, or progression to accelerated/blast phase; quantitative RT-PCR recommended for monitoring and remission confirmation.

    NCCN Chronic Myeloid Leukemia guidance.

    AML: NGS multiplex panels and targeted NGS recommended for initial evaluation, prognostication, and management; recommended genes include FLT3, NPM1, CEBPA, IDH1/2, KIT, and TP53.

    NCCN Acute Myeloid Leukemia guidance.

    ALL (adult and pediatric): Comprehensive NGS testing for gene fusions and pathogenic mutations for prognostic risk stratification; ABL1/BCR-ABL1 kinase domain testing for relapsed/refractory Ph+ B-ALL; NTRK fusion analysis recommended for risk stratification.

    NCCN ALL and Pediatric ALL guidance.

    CLL/SLL & B-cell lymphomas: IGHV somatic hypermutation analysis and FISH (eg, +12; del(11q); del(13q); del(17p)) recommended for diagnosis, prognostication, and therapy planning; TP53 sequencing analysis recommended for CLL/SLL and mantle cell lymphoma to direct treatment selection.

    NCCN CLL/SLL and B-Cell Lymphomas guidance.

    Multiple Myeloma: Baseline clone identification for MRD and FISH panel at initial workup for prognostic purposes (recommended FISH: del(13), del(17p13), t(4;14), t(11;14), t(14;16), t(14;20), 1q21 gain/amplification, 1p deletion).

    NCCN Multiple Myeloma guidance.

    MRD testing recommended at multiple time points (eg, pre-induction, post-consolidation, serial monitoring) and may use NGS, PCR, or flow cytometry; baseline clone identification and sample storage recommended where applicable.

    NCCN MRD guidance.

    Guideline-concordant testing

    Covered when consistent with cited guideline recommendations and medical necessity:

    CLL/SLL FISH: FISH testing including +12; del(11q); del(13q); del(17p) during diagnostic workup is recommended and informative for prognosis/therapy; rule out mantle cell lymphoma via FISH for t(11;14) when indicated.

    NCCN CLL/SLL guidance.

    Multiple myeloma FISH: FISH testing during initial workup for prognostic purposes including del(13), del(17p13), t(4;14), t(11;14), t(14;16), t(14;20), 1q21 gain/amplification, 1p deletion.

    NCCN Multiple Myeloma guidance.

    AML mutation testing (including PML-RARA): All patients with AML should be tested for specified gene mutations; PML-RARA alpha is included among genetic markers to test.

    NCCN AML guidance.

    RBC genotyping prior to anti-CD38 therapy: Consider baseline RBC phenotype and genotype prior to initiation of anti-CD38 monoclonal antibody treatment to mitigate anti-CD38 interference with serologic testing.

    AABB bulletin updated April 2024.

    Broad RNA fusion panel tests that use RNA analysis alone and include 51 or more genes are reasonable and necessary only when performed as part of the diagnostic workup for adult or pediatric acute lymphoblastic leukemia (ALL). The policy explicitly states that RNA-only fusion panels meeting the ≥51 gene threshold are considered not reasonable and necessary for all other indications.

    Broad molecular profiling panels and myeloid malignancy panels performed on bone marrow or peripheral blood are covered only for the specific indications listed in the policy (see criteria for AML, newly diagnosed ALL, newly diagnosed MDS, suspected MDS with other causes of cytopenia ruled out, suspected MPN when initial genetic evaluation or prior JAK2/CALR/MPL testing is negative, CML with progression to accelerated/blast phase or negative BCR-ABL1 kinase domain mutation analysis, and diffuse large B-cell lymphoma). The policy notes that appropriate multigene panel coding should be used and references NCCN guidance supporting use of multigene NGS panels in selected hematologic malignancies (for example, MPN panels that include JAK2, CALR, and MPL and B‑cell lymphoma panels that include >50 genes).

    Within the provided excerpt there are no additional explicit exclusion statements beyond those specifying that certain broad panels are not reasonable and necessary outside the listed indications; the references section and guideline citations do not introduce further named exclusions in this excerpt.

    This document excerpt does not list any further explicit exclusions for molecular testing beyond the policy statements that limit coverage to the specified indications and the guideline-aligned recommendations. No additional named exclusions are provided in the cited sections.

    Any use of the described broad RNA fusion panels (RNA-only panels with ≥51 genes) or broad molecular profiling/myeloid panels outside the specific indications enumerated in the policy is considered not reasonable and necessary. The policy language makes this limitation explicit for RNA-only fusion panels and for broad molecular/myeloid panels performed on bone marrow or peripheral blood.

    All indications for broad molecular profiling panels and myeloid malignancy panels that are not explicitly listed in the policy are considered not reasonable and necessary. The policy directs that multigene panels be coded appropriately and clarifies that these clinical criteria do not address liquid biopsy testing.

    In the provided document chunks there are no explicit statements framed with the phrase 'not medically necessary' beyond the policy’s clear descriptions that certain broad panels are not reasonable and necessary outside the listed indications. The NCCN guideline citations support where multigene testing is appropriate but do not add separate 'not medically necessary' phrasing in these excerpts.

    This excerpt does not contain any additional explicit statements labeled 'not medically necessary.' The policy instead uses the term 'not reasonable and necessary' to describe coverage limits for broad RNA fusion and broad molecular/myeloid panels when used outside specified indications.

    Procedure and Billing Codes

    Referenced CPT/HCPCS/PLA codes in policy reference tablesmixed
    81456Molecular profiling panels - example listed in reference table
    81450Targeted gene panel, example in reference table
    81455Targeted gene panel, example in reference table
    81170ABL1 kinase domain analysis
    0364UClonoSEQ Tracking (MRD) Assay
    0016UBCR/ABL1 RNA Quantitative with Interpretation
    0040UMRDx BCR-ABL Test
    81219CALR mutation analysis
    81218CEBPA mutation analysis / related assays
    81206Example cytogenetic/molecular test codes listed
    1–10 of 26
    1/3
    Panel coding guidancemixed
    affected codesAppropriate multigene panel codes should be used when a multigene panel is performed (document notes panels should be coded appropriately).
    Prior authorization affected codesmixed
    affected codesPlaceholder — specific CPT/HCPCS codes are not provided in these chunks
    Molecular and genomic procedure codes listedmixed
    0001URBC DNA HEA 35 AG 11 BLD GRP WHL BLD CMN ALLEL
    0016UONC HMTLMF NEO RNA BCR/ABL1 BLD/BNE MARROW
    0017UONC HMTLMF NEO JAK2 MUTATION DNA BLD/BNE MARROW
    0023UONC AML DNA GNTYP INT TANDEM DUP DETCJ/NONDETCJ
    0027UJAK2 GENE ANALYSIS TRGT SEQ ALYS EXONS 12-15
    0040UBCR/ABL1 GENE TLCJ ALYS MAJOR BP QUANTITATIVE
    0046UFLT3 GENE INT TANDEM DUPL VARIANTS QUANTITATIVE
    0049UNPM1 GENE ANALYSIS QUANTITATIVE
    0050UTRGT GEN SEQ ALYS AML 194 GENE INTERROG SEQ VRNT
    0171UTARGETED GENOMIC SEQUENCE ALYS PNL DNA 23 GENES
    1–10 of 44
    1/5
    Gene count threshold for RNA fusion panels — RNA fusion panels
    RNA fusion panel gene-count threshold>= 51 genes (RNA analysis alone)
    Coverage indicationCovered only for diagnostic workup of adult or pediatric acute lymphoblastic leukemia (ALL)
    Not coveredNot reasonable and necessary for all other indications
    NGS panel gene count (B‑cell lymphoma)
    Minimum gene count for B‑cell lymphoma NGS panels>50 genes (NGS panel recommended to include more than 50 genes)
    Specimen sourcesPanels performed on bone marrow or peripheral blood
    Guideline sourceNCCN B-Cell Lymphomas recommendation for NGS panel (BCEL-1) including >50 clinically associated genes
    Gene panel size examples and codes
    Targeted panel size examplesTargeted panels of 5–50 genes (CPT 81451)
    Larger panel examplesPanels of 51 or more genes (CPT 81455, 81456)
    Coding guidanceUse appropriate panel CPT/PLA codes when multigene panels are performed (see reference tables)

    Prior Authorization, Documentation, and Operational Notes

    Prior Authorization

    Obtain prior authorization (policy-level)

    Preauthorization is required for hematologic malignancy molecular diagnostic testing under this policy; when applicable, CMS national or local coverage determinations (NCD/LCD) take precedence.

    Prior Authorization

    Prior authorization required for broad and myeloid panels

    Obtain prior authorization before performing broad molecular profiling panels, myeloid malignancy panels, or listed single-gene/focused panels on bone marrow or peripheral blood when used for the policy-specified indications.

    Prior Authorization

    Policy requires preauthorization for hematologic molecular diagnostics

    The policy title and content indicate preauthorization is required for hematologic malignancy molecular diagnostics; follow the insurer's prior authorization process for tests covered by this policy.

    Prior Authorization

    Prior authorization required for listed CPT/PLA codes

    Submit prior authorization for the specific molecular pathology and genomic procedure codes listed in the policy reference tables before testing.

    • Examples of listed codes include 0016U, 0017U, 0023U, 0040U, 0046U, 0049U, 81170, 81451, 81455, 81456, and 0001U (see policy tables for full list).
    Step Therapy

    Allow stepwise testing or NGS panel for MPN

    NCCN guidance allows either stepwise testing or an NGS multigene panel that includes JAK2, CALR, and MPL for suspected MPN; providers may follow stepwise testing or order an NGS panel that includes these genes.

    • For suspected MPN, panel must include at minimum JAK2, CALR, and MPL per policy (chunk 21).
    Documentation Required

    Pre-test counseling and coding guidance

    Discuss with patients the potential for incidental germline findings before performing somatic mutation profiling and ensure coding reflects the performed multigene panel when applicable.

    • Inform patients that somatic testing can uncover clinically relevant germline variants (chunk 5).
    • If a multigene panel is performed, use appropriate panel CPT codes as noted in the policy (chunks 6 and 19).
    Billing Rule

    Use appropriate panel CPT codes; liquid biopsies not addressed

    When a multigene panel is performed, bill using the appropriate multigene/panel CPT code; note that the clinical criteria do not address liquid biopsies.

    • Policy note: 'If a multigene panel is performed, appropriate panel codes should be used.' (chunk 19).
    • Reference table lists example panel codes (chunk 6).
    Documentation Required

    Follow recommended laboratory methods and document intent

    When indicated by NCCN or test-specific guidance, use quantitative or qualitative RT-PCR, FISH, or multiplex RT-PCR for assays such as BCR-ABL1 and document diagnostic intent and monitoring implications.

    • NCCN recommends evaluation for BCR-ABL1 via FISH or multiplex RT-PCR and quantitative RT-PCR for monitoring (chunk 44).
    Documentation Required

    Consider baseline RBC genotyping before anti‑CD38 therapy

    Consider baseline red blood cell phenotype and genotype prior to initiating anti‑CD38 monoclonal antibody therapy; document the clinical rationale to support testing.

    • AABB bulletin (updated April 2024) recommends consideration of baseline phenotype/genotype to mitigate anti‑CD38 interference with serologic testing (chunk 57).
    Denial Risk

    Denial risk: unsupported use of ≥51‑gene RNA fusion panels

    Do not perform broad RNA fusion panels with 51 or more genes using RNA analysis alone for indications other than diagnostic workup for adult or pediatric ALL; such uses are considered not reasonable and necessary and may be denied.

    • Policy: 'RNA fusion panel tests with 51 or more genes utilizing RNA analysis alone ... may be considered reasonable and necessary when: the member is undergoing diagnostic workup for adult or pediatric ALL.' (chunk 17).
    • Policy: '... are considered not reasonable and necessary for all other indications.' (chunk 17).
    Denial Risk

    Denial risk for panels ordered outside listed indications

    Broad molecular profiling panels and myeloid malignancy panels performed for indications not explicitly listed in the policy are considered not reasonable and necessary and are at risk for denial.

    • Policy: 'Broad molecular profiling panels ... are considered not reasonable and necessary for all other indications.' (chunk 19).
    Note

    Verify procedure/diagnosis code pairs with Quick Code Search

    Use the Quick Code Search tool to check whether a procedure/diagnosis code pair is listed and how it will be adjudicated prior to submission; code-pair lookup may indicate approval, denial, or review.

    • Quick Code Search instructions: enter procedure code then diagnosis code to see if the pair will be approved, denied, or held for review (chunk 58).
    Note
    Note
    Step Therapy

    No insurer step therapy sequencing specified

    No formal step therapy sequencing is described in this excerpt; specific step therapy requirements are not provided. The policy emphasizes baseline testing prior to anti‑CD38 therapy rather than sequencing of molecular tests.

    • Policy states NCCN allows stepwise testing for MPN but does not prescribe insurer step therapy sequencing (chunk 36).
    • Policy notes baseline RBC genotyping recommendation before anti‑CD38 therapy (chunk 57).
    Note

    Operational denial triggers not provided in excerpt

    Operational denial triggers and detailed prior‑authorization workflows are not specified in the provided excerpt; follow the insurer's published prior authorization process and the policy's coverage criteria when submitting requests.

    Key Terms and Definitions

    Somatic mutation profiling — definition
    DefinitionSomatic mutation profiling: molecular testing to identify somatic (tumor) variants for diagnosis, prognosis, and treatment selection
    Pre-test counselingProviders should communicate potential for incidental germline findings prior to somatic profiling
    ScopeUsed across hematologic malignancy evaluations per policy
    Myeloproliferative Neoplasm (MPN) — definition and examples
    DefinitionMyeloproliferative neoplasm (MPN): a group of disorders in which bone marrow makes too many blood cells (includes CML, PV, PMF, ET, chronic neutrophilic/eosinophilic leukemia, MPN-U)
    Clinical noteNCCN recommends molecular testing (JAK2, CALR, MPL) in the initial workup; multigene NGS panels including these genes are acceptable alternatives to stepwise testing
    Indication for panelsMPN molecular profiling panels required to include at minimum JAK2, CALR, and MPL
    Myelodysplastic Syndrome (MDS) — definition
    DefinitionMyelodysplastic syndrome (MDS): disorder with bone marrow abnormalities leading to cytopenias; WHO recognizes multiple subtypes (eg, MDS-MLD, MDS-SLD, MDS-RS, MDS-EB, MDS with isolated del(5q))
    Testing guidanceGenetic testing for somatic mutations associated with MDS is recommended during initial evaluation
    Use casesSupports diagnosis, prognostication, and treatment decision-making
    Minimal Residual Disease (MRD) — definition
    DefinitionMinimal (measurable) residual disease (MRD): testing to detect low levels of residual malignant cells after therapy (methods include NGS, PCR, flow cytometry)
    TimingRecommended at multiple time points (eg, pre-induction, post-consolidation, serial monitoring) and may be used for baseline clone identification
    SpecimenPerformed on bone marrow or peripheral blood as indicated
    Broad molecular profiling / NGS multigene panel — definition
    DefinitionBroad molecular profiling / NGS multigene panel: next‑generation sequencing panels that assess multiple genes for diagnosis, prognostication, and treatment guidance
    ExamplesPanels may include gene sets such as JAK2, CALR, MPL for MPNs or >50 genes for B‑cell lymphoma panels
    SpecimensPerformed on bone marrow or peripheral blood
    CLL/SLL FISH panel — contents
    Panel contentsCLL/SLL FISH panel includes +12; del(11q); del(13q); del(17p)
    Additional testingFISH to rule out mantle cell lymphoma via t(11;14) when indicated (eg, initial diagnosis by flow cytometry)
    PurposeInformative for prognostic and/or therapy determination in CLL/SLL
    Multiple myeloma FISH panel — contents
    Panel contentsMultiple myeloma FISH panel includes del(13), del(17p13), t(4;14), t(11;14), t(14;16), t(14;20), 1q21 gain/amplification, and 1p deletion
    PurposeRecommended during initial workup for prognostic purposes
    Guideline sourceNCCN Multiple Myeloma guidance (2.2026)
    PML-RARA testing — recommendation
    Test typesPML-RARA testing via qualitative FISH and PCR
    IndicationRecommended in initial diagnostic evaluation of acute myeloid leukemia (AML)
    Guideline notePML-RARA alpha listed among genetic markers to test in all patients with AML

    Line of Therapy Context

    salvage

    salvage: Repeat broad molecular profiling panels may be considered in relapsed/refractory settings as specified for MDS post-allo-HCT; ALL symptomatic relapse after maintenance; and AML relapsed/refractory after consolidation or progression on treatment.

    Line of therapy: salvage.

    salvage

    salvage: Repeat broad molecular profiling panels may be considered for MDS relapsed after allo-HCT; ALL with symptomatic relapse after maintenance; AML relapsed/refractory after consolidation or progression on treatment.

    Line of therapy: salvage; supports repeat testing scenarios.

    salvage

    salvage: BCR-ABL1 kinase domain testing recommended when failing treatment milestones, loss of response, or progression to accelerated/blast phase; molecular monitoring (quantitative RT-PCR) recommended indefinitely for TKI discontinuation criteria.

    Line of therapy: salvage; NCCN CML guidance.

    first-line

    first-line: NGS multiplex panels and targeted NGS are recommended during initial evaluation for adult patients with AML for prognostication and therapy selection.

    Line of therapy: first-line; NCCN AML guidance.

    first-line

    first-line: FISH and genomic testing recommended during initial diagnostic/prognostic workup for multiple myeloma and CLL/SLL; RBC genotyping considered prior to initiation of anti-CD38 therapy.

    Line of therapy: first-line; NCCN and AABB guidance.

    Required and Recommended Biomarkers

    BCR-ABL1 — biomarker
    MarkerBCR-ABL1 (kinase domain analysis and FISH/quantitative tests)
    IndicationsUsed for CML, Ph+ ALL, diagnostic workup, monitoring, and when assessing TKI response or progression
    Testing methodsQualitative/quantitative RT-PCR, FISH, and kinase domain sequencing as appropriate
    JAK2, CALR, MPL — biomarker set
    MarkersJAK2, CALR, MPL (minimum gene set)
    IndicationRequired for initial genetic evaluation of suspected MPN; panels should include these genes
    Testing approachStepwise single-gene testing or multigene NGS panel including these genes per NCCN
    FLT3, NPM1, IDH1/IDH2, TP53, CEBPA, KIT — biomarkers
    Common AML biomarkersFLT3, NPM1, IDH1, IDH2, TP53, CEBPA, KIT
    IndicationRecommended as part of molecular testing during evaluation for AML (prognosis and therapeutic decisions)
    Reference codes/examplesVarious variant analysis codes listed in reference tables (eg, 81120, 81310, 81218, 81272)
    JAK2 — biomarker
    MarkerJAK2 (specific)
    RolePrimary gene tested for suspected MPN and included in multigene panels for MPN workup
    Coding examplesJAK2-related CPT/PLA entries appear in reference tables (eg, 81270, 81279, 0017U)
    CALR — biomarker
    MarkerCALR (specific)
    RoleIncluded in initial MPN workup and multigene panels; also referenced for MDS evaluation
    Guideline sourceNCCN Myeloproliferative Neoplasms and Myelodysplastic Syndromes guidance
    MPL — biomarker
    MarkerMPL (specific)
    RoleIncluded in initial MPN workup and multigene panels; recommended for MDS and MPN evaluations
    Coding examplesMPL-related codes appear in reference tables (eg, 81338, 81339)
    Consolidated biomarkers for hematologic malignancy testing
    Consolidated biomarker listFLT3, IDH1, IDH2, BCR-ABL1, TP53, NPM1, CEBPA, KIT, JAK2, IGHV, CALR, MPL
    UseThese markers are referenced across tumor-specific indications for diagnosis, prognostication, monitoring, and treatment selection
    SpecimenMost performed on bone marrow or peripheral blood as specified by indication
    JAK2 — additional references
    JAK2 referencesReferenced repeatedly as core gene for MPN testing and included in NCCN-recommended panels
    Clinical roleInitial diagnostic testing for suspected MPN and part of prognostic testing post-diagnosis
    Coding examplesAssociated CPT/PLA entries in reference tables (eg, 0017U, 0027U, 81270)
    CALR — additional references
    CALR referencesCALR recommended in initial MPN workup and included in panels per NCCN guidance
    Clinical roleTest for suspected MPN and as part of multigene prognostic panels
    Guideline sourceNCCN Myeloproliferative Neoplasms guidance
    MPL — additional references
    MPL referencesMPL included in NCCN-recommended panels for MPN and referenced for MDS testing
    Clinical rolePart of initial evaluation and prognostication panels
    Coding examplesMPL-related CPT codes listed in reference tables
    FLT3 — biomarker
    MarkerFLT3
    IndicationsSuspected or confirmed AML; also relevant in ALL and MDS/MPN contexts per tumor-specific recommendations
    Guideline sourceNCCN AML and ALL guidance
    TP53 — biomarker
    MarkerTP53
    IndicationsTesting indicated for AML, CLL/SLL, mantle cell lymphoma workup, and multiple myeloma prognostic assessment
    PurposePrognostic and treatment-selection implications per NCCN guidance
    NTRK fusions — biomarker
    MarkerNTRK fusions
    IndicationRecommended for risk stratification in acute lymphoblastic leukemia (ALL)
    Testing methodsFISH or IHC per NCCN guidance
    IGHV somatic hypermutation — biomarker
    MarkerIGHV somatic hypermutation
    IndicationWorkup/diagnosis of CLL, SLL, primary cutaneous B-cell lymphoma, or other B-cell lymphomas for prognostic/therapy decisions
    Guideline sourceNCCN CLL/SLL guidance
    Cytogenetic FISH markers — CLL/SLL
    Cytogenetic FISH markers (CLL/SLL)del(17p), del(11q), del(13q), +12, t(11;14)
    PurposeDiagnostic workup and prognostic/therapy determination in CLL/SLL
    Testing guidanceRule out mantle cell lymphoma via t(11;14) when indicated
    Multiple myeloma cytogenetic markers — FISH panel
    Multiple myeloma cytogenetic markersdel(13), del(17p13), t(4;14), t(11;14), t(14;16), t(14;20), 1q21 gain/amplification, 1p deletion
    PurposeRecommended during initial workup for prognostic assessment
    Guideline sourceNCCN Multiple Myeloma guidance (2.2026)
    PML-RARA — biomarker
    MarkerPML-RARA
    Testing methodsQualitative FISH and PCR for PML-RARA rearrangement
    IndicationRecommended in AML diagnostic evaluation; PML-RARA alpha included among markers to test in all patients with AML

    Clinical Context and Rationale

    Molecular diagnostic testing in hematologic malignancies is used to identify biomarkers for diagnosis, prognosis, therapy selection, and monitoring; guideline citations (NCCN) are referenced to align coverage with recommended testing strategies. The policy highlights examples where multigene NGS panels are appropriate (for instance, MPN panels that include JAK2, CALR, and MPL or B‑cell lymphoma panels with at least >50 genes), and it notes that stepwise testing is an acceptable alternative when indicated by guidelines.

    Policy Revision Timeline

    2026-05-01policy_effectiveLatest

    Policy M.77 (Hematologic Malignancy Molecular Diagnostics) became effective.